AGE-induced neuronal cell death is enhanced in G2019S LRRK2 mutation with increased RAGE expression

Hyun Jin Cho, Chengsong Xie and Huaibin Cai

Abstract

Background: Leucine-rich repeat kinase 2 (LRRK2) mutations represent the most common genetic cause of sporadic and familial Parkinson’s disease (PD). Especially, LRRK2 G2019S missense mutation has been identified as the most prevalent genetic cause in the late-onset PD. Advanced glycation end products (AGEs) are produced in high amounts in diabetes and diverse aging-related disorders, such as cardiovascular disease, renal disease, and neurological disease. AGEs trigger intracellular signaling pathway associated with oxidative stress and inflammation as well as cell death. RAGE, receptor of AGEs, is activated by interaction with AGEs and mediates AGE-induced cytotoxicity. Whether AGE and RAGE are involved in the pathogenesis of mutant LRRK2 is unknown.

Methods: Using cell lines transfected with mutant LRRK2 as well as primary neuronal cultures derived from LRRK2 wild-type (WT) and G2019S transgenic mice, we compared the impact of AGE treatment on the survival of control and mutant cells by immunostaining. We also examined the levels of RAGE proteins in the brains of transgenic mice and PD patients by western blots.

Results: We show that LRRK2 G2019S mutant-expressing neurons were more sensitive to AGE-induced cell death compared to controls. Furthermore, we found that the levels of RAGE proteins were upregulated in LRRK2 G2019S mutant cells.

Conclusions: These data suggest that enhanced AGE-RAGE interaction contributes to LRRK2 G2019S mutation-mediated progressive neuronal loss in PD.

Keywords: Parkinson’s disease, LRRK2, G2019S, AGE, RAGE, Neuronal death

Background

Parkinson’s disease (PD) is the second most common neurodegenerative disease with progressive loss of pigmented dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) [1]. Although the majority of PD cases are sporadic, genetic studies of familial PD patients have identified mutations in more than 15 genes as causal factors for PD [2, 3]. Among PD-related causal genes, leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of sporadic and familial PD, as well as the late-onset PD [4]. Up to now, more than 100 mutations of LRRK2 have been reported to be related to PD. Especially, the G2019S mutation has been identified as the most prevalent genetic cause of familial and sporadic PD [5]. Despite the relatively high prevalence, the penetrance of LRRK2 G2019S mutation is incomplete and age-dependent [5]. Therefore, it has been speculated that aging-related factors could also contribute to G2019S LRRK2-linked PD pathogenesis.

Advanced glycation end products (AGEs), raised from the reaction of sugars with certain amino acids or fats, are formed in high amounts in diabetes and also in the physiological organism during aging [6–9]. They have been implicated in numerous diabetes- and aging-related disorders such as cardiovascular disease, renal disease, and neurological disease by inducing oxidative stress, inflammation, and cell death [10–13]. Receptor of AGEs (RAGE), which belongs to the trans-membranous
receptor of the immunoglobulin superfamily, is activated by several ligands including amyloid beta oligomers, calcium-binding proteins (S100 Calgranulins), and high-mobility group box-1 protein (HMGBl), as well as AGEs [14, 15]. Moreover, RAGE reveals high expression levels in neurons in neurodegenerative disorders, such as PD and Alzheimer’s disease (AD) [16]. In pathological environments, like PD and AD, RAGE expression is often upregulated with increased amounts of its ligands as well. Engagement of RAGE by AGE has shown to generate reactive oxygen species (ROS) via RAGE-mediated intracellular signaling and to accelerate pro-inflammatory events in cells.

Based on these earlier studies, we hypothesized that AGE-RAGE interaction might contribute to progressive neuronal cell death in G2019S LRRK2 mutation-expressing cells. In this study, we used LRRK2 G2019S overexpressing mouse model for in vitro neuronal culture experiments and demonstrated that LRRK2 G2019S mutant-expressing neurons were more sensitive to AGE-induced toxicity compared to the controls. In addition, RAGE levels were upregulated in LRRK G2019S mutant cells, suggesting enhanced AGE-RAGE activation is involved in LRRK2 G2019S mutation-related progressive neuronal loss.

Methods
Cell line and mouse primary neuron culture
HEK293 cells were culture in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) containing a high glucose concentration supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin. For the transfection, Fugene HD (Roche) was used. Primary neurons from cortex and striatum were prepared from newborn pups (postnatal day 0) [17]. Briefly, cells were dissociated by papain (Worthington Biochemical Corp) solution and then placed in poly-D-lysine (BD Bioscience) plate in Basal Eagle Medium (Sigma-Aldrich) supplemented with 1 mM L-glutamine, B27, N2, and penicillin/streptomycin (Invitrogen). To prevent glial cell growth, arabinosylcytosine 1 mM L-glutamine, B27, N2, and penicillin/streptomycin. Basal Eagle Medium (Sigma-Aldrich) supplemented with 0.1% Triton X-100 in PBS. After blocking nonspecific staining using 10% goat serum (Sigma-Aldrich), primary antibodies used included MAP2 (SantaCruz), GFAP (Sigma-Aldrich), and NeuN (Millipore). To detect RAGE protein, primary antibodies from SantaCruz and R&D were used. Anti-LRRK2 polyclonal antibodies (4EC9E and 4C84E) were kindly provided from Dr. Jean-Marc Taymans. Alexa 488 and 568-conjugated secondary antibody was incubated to visualize the staining. Fluorescent images were captured by a Zeiss confocal microscope (LSM 510 META).

Immunofluorescence staining
For immunocytochemistry, cultured neurons were fixed with 4% paraformaldehyde (PFA) and permeabilized with 0.1% Triton X-100 in PBS. After blocking nonspecific staining using 10% goat serum (Sigma-Aldrich) for 1 h, cells were incubated with primary antibodies overnight. For immunohistochemistry, mice were perfused via cardiac infusion with 4% PFA in cold PBS. To prepare frozen sections, brain was removed and submerged in 30% sucrose for 24 h and then sectioned at 40 μm thickness using cryostat (Leica CM1950). Primary antibodies used included MAP2 (SantaCruz), GFAP (Sigma-Aldrich), and NeuN (Millipore). To detect RAGE protein, primary antibodies from SantaCruz and R&D were used. Anti-LRRK2 polyclonal antibodies (4EC9E and 4C84E) were kindly provided from Dr. Jean-Marc Taymans. Alexa 488 or 568-conjugated secondary antibody was incubated to visualize the staining. Fluorescent images were captured by a Zeiss confocal microscope (LSM 510 META).

Generation of LRRK2 inducible transgenic mice
The cDNA fragments encoding full-length human G2019S LRRK2 mutant was inserted into a tetracycline operator-regulated gene expression vector, pPrP-tetP. To facilitate protein identification, C-termini of human G2019S LRRK2 protein were tagged by hemagglutinin (HA) epitope. The F1 transgenic mice were crossed with CaMKII-tTA mice to achieve high expression of LRRK2 G2019S in the forebrain [18]. The mice were fed regular diet ad libitum and housed in a 12 h light/dark cycle. All mouse work followed the guidelines approved by the Institutional Animal Care and Use Committees of the National Institute of Child Health and Human Development.

Preparation of protein extracts and western blot
Mouse brain tissue was homogenized with 10 volumes of sucrose buffer (0.32 M sucrose, 1 mM MgCl2, 1 mM NaHCO3, and 0.5 mM CaCl2) containing protease and...
phosphatase inhibitor cocktail (Roche). To obtain crude membrane fraction, homogenized brain samples were centrifuged at 1000 × g for 10 min to remove nuclear fraction and then supernatants were centrifuged at 20,000 × g for 20 min. The pellet fraction was dissolved in RIPA buffer by sonication and concentrations were measured by BCA assay. Proteins were analyzed by 4-12% NuPage BisTris-polyacrylamide gel electrophoresis (Invitrogen) in MOPS running buffer (Invitrogen) and transferred to polyvinylidene difluoride (PVDF) membranes. The signals were visualized by enhanced chemiluminescence development (Pierce) and quantified using Scion Image System (Frederick, MD).

Human brain tissues
Striatal tissues were obtained from the brain bank of Johns Hopkins University School of Medicine. Subjects or their legal representatives signed informed consents approved by the Johns Hopkins Institutional Review Boards. The diagnosis of PD was made based on the clinicopathological criteria including characteristic clinical features and on the presence of Lewy bodies within the pigmented neurons lost in the substantia nigra. The average age at death for the PD subjects included in this study was 80 + 6.9 years old, while for the NPC subjects it was 85 + 6.6 years old.

Statistical analysis
Statistical analysis was performed with GraphPad Prism 5 (GraphPad Software). Statistical significances were obtained by comparing means of different case using t test or ANOVA followed by Tukey’s honestly significant difference test. Error bars indicate SD. *P < 0.05; **P < 0.01; ***P < 0.001.

Results
Characterization of AGE in cultured primary neurons
To test the toxic effects of AGEs generated for the cell viability assay, we first treated HEK293 cells with increasing dose of AGEs (Fig 1a). After treated with AGEs for 24 h, more HEK293 cells were lost at higher AGE dosages, whereas cells incubated with BSA showed no obvious cell death (Fig. 1a). Since LRRK2 is more abundant in the striatum [19], we cultured neurons from striatum of postnatal day 0 (P0) pups for AGE treatment. After 15 days in vitro culture (15 DIV), the cultured striatal neurons were incubated with AGEs at the concentrations of 0.0125, 0.025, 0.05, 0.1, and 0.2 μg/μl for 24 h and the cells were immuno-stained with anti-MAP2 and anti-GFAP antibodies to count the surviving neurons and astrocytes, respectively (Fig 1b). Cultured striatal neurons showed a number of neurites and healthy morphologies at the 0.0125 to 0.05 μg/μl AGE treatment. At the 0.1 μg/μl AGE-treated cases, we observed fragmented neurites but not neuronal loss. By contrast, almost all MAP2-positive neurons were dead after incubated with 0.2 and 0.4 μg/μl AGE for 24 h. On the other hand, GFAP-positive astrocytes were less sensitive to AGEs on the same condition. Based on these findings, in the later experiments, we treated cultured striatal neurons with AGE at the concentrations of 0.1–0.15 μg/μl for 24 h.

LRRK2 G2019S-expressing neurons are more sensitive against AGE
Next, we cultured the striatal neurons (DIV 15) from the striatum of P0 G2019S LRRK2 transgenic (Tg) and wild-type (WT) LRRK2 Tg pups to investigate whether these neurons exhibit different vulnerability to AGEs at 0.1 and 0.15 μg/μl after 24 h treatment (Fig 2a). We found more than 60% loss of G2019S LRRK2-expressing neurons compared to the WT LRRK2 cultures after treated with 0.1 μg/μl AGEs for 24 h (Fig. 2a). The surviving G2019S LRRK2-expressing neurons exhibited severe neurite fragmentation and condensed cell body, while control neurons showed only slight neurite fragmentation (Fig. 2a). After treated with AGEs at 0.15 μg/μl for 24 h, more severe loss of G2019S LRRK2-expressing neurons as well as WT neurons was observed (Fig. 2a, b). These data indicate that G2019S LRRK2-expressing neurons are much more sensitive to AGE-induced toxicity compared to neurons expressing WT LRRK2.

AGE-induced neuronal cell death is mediated by RAGE
We then investigated whether AGE-induced neuronal cell death in LRRK2 G2019S neurons is mediated by any specific intracellular signaling pathways. Receptor of AGE (RAGE) is reported to be expressed in aged brains. Therefore, we hypothesized that neuronal cell death triggered by AGE is mediated by RAGE. To test the role of RAGE, we neutralized RAGE function using anti-RAGE antiserum in LRRK2 G2019S neurons (Fig. 3a). As a result, severe cell death induced by 0.1 μg/μl AGE treatment was remarkably mitigated by pre-incubation of anti-RAGE antiserum (Fig. 3a, b). This event indicates that RAGE-related pathway participates AGE-induced neuronal cell death in LRRK2 G2019S mutation.

Upregulation of RAGE protein levels in G2019S LRRK2 samples
To test whether RAGE protein levels are regulated by G2019S LRRK2 expression, HEK293 cells were transfected with doxycycline (DOX)-activated G2019S LRRK2 expression constructs (Fig. 4a). We found enhanced RAGE protein levels in cells treated by DOX (Fig. 4a, b). Also, we observed increased levels of RAGE proteins in the G2019S LRRK2 expressing striatal neuron cultures compared to control neurons (Fig. 4c, d). Next, the
striatal tissues from 3-month-old G2019S LRRK2 transgenic and littermate non-transgenic (nTG) mice were dissected and total proteins were extracted for analyses of RAGE expression. Since RAGE is a type I transmembrane protein, crude membrane proteins were also prepared to examine the RAGE protein levels. Significantly increased RAGE levels were presented in both total lysates and crude membrane extracts of the brains from G2019S LRRK2 mutant mice (Fig. 4e-g). Furthermore, immunostaining with anti-RAGE antibody also confirmed the increase of RAGE levels in the cultured striatal neurons from G2019S LRRK2 P0 pups compared to the WT LRRK2 (Fig. 4h, i). These results provide strong evidence of upregulated RAGE protein expression in the G2019S LRRK2-expressing mouse brains.

Increased level of RAGE protein in the brains of PD patients
Finally, we examined the levels of RAGE proteins in the human brain samples from sporadic PD patients and age-matched control subjects. We tested total protein lysates extracted from striatal tissues. As expected, significantly increased RAGE expression in the striatum from sporadic PD patients was detected by the western blotting (Fig. 5). This upregulation of RAGE protein...
levels in the striatum of PD patients supports the involvement of AGE-RAGE pathway in PD pathogenesis.

**Discussion**

Diverse mutations in LRRK2 underlie the most common genetic cause of familial and sporadic PD. Since the identification of PD-associated mutations in LRRK2, many studies have attempted to illustrate the potential pathogenic mechanisms of the neuronal cell death caused by mutant LRRK2, especially the G2019S mutation. Here, we demonstrated that AGE-induced toxicity in the striatal neurons was enhanced in the presence of G2019S LRRK2.
G2019S LRRK2. Furthermore, we found that the level of RAGE, the critical mediator of AGE-induced cell death, was upregulated in the G2019S LRRK2-expressing neurons. This finding was confirmed in diverse experimental systems, including G2019S LRRK2-expressing cell lines, primary neurons, and mouse brain extracts, as well as postmortem PD striatal tissues. These results reveal a previously unknown pathogenic mechanism of LRRK2 G2019S mutation in AGE/RAGE-mediated cytotoxicity.

We detected elevated protein levels of RAGE but not mRNA levels (data not shown) in G2019S LRRK2, indicating the possibility that the upregulation of RAGE mRNA translation by G201S LRRK2, resulting from the pathologically enhanced kinase activity of G2019S mutation. Also, in support that increased RAGE protein levels are not the results from artificially over-expressed G2019S LRRK2, we checked the AGE-induced cell toxicity and RAGE levels in the wild-type LRRK2 overexpressing neurons. We found significant changes of RAGE levels between wild-type LRRK2 and G2019S LRRK2 overexpressing neurons, indicating that this event is not resulted from artificial transgene expression.
AGEs, the senescent protein derivatives are formed at accelerated rate under normal aging process, which elicit reactive oxygen species generation and inflammation, and subsequently alters diverse gene expressions, apoptotic neuronal cell death [20–22]. It has been reported that AGE-albumin, the most abundant AGE product, is synthesized and secreted from the cells and studied as a key inducer of host cell death in various neurodegenerative disorders by enhanced expression of RAGE [23]. Gomez et al. showed increased level of RAGE in the frontal cortex of sporadic PD brains [16]. In line with this early study, we found increased RAGE protein levels in the striatum of PD patients, as well as LRRK2 G2019S transgenic mice at 3 months of age.

Conclusions

In summary, we demonstrate that AGE-RAGE cascades are involved in G2019S LRRK2-mediated pathogenesis in PD. Our study suggests that targeted pharmacological interventions using inhibitors or antagonist, such as RAGE neutralizing antisera, or inhibitors against AGE-RAGE intracellular signaling may serve as promising therapeutic strategies to slow down the progression of PD, especially, PD patients having G2019 LRRK2 mutation.

Acknowledgements

We want to thank members of Cai lab for their suggestions and technical assistance and Dr. Juan Troncoso from the Johns Hopkins University School of Medicine for providing the striatal tissues.

Funding

This work was supported by the intramural research programs of National Institute on Aging, National Institutes of Health (HIC: AG000944).

Availability of data and materials

The materials used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

HJC and HC wrote the manuscript. HJC performed immunostaining and western blot experiments. CX performed primary neuron cultures. HJC carried out data analyses. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This mouse protocol was approved by the ACUC of the intramural research programs of National Institute on Aging, National Institutes of Health (protocol number: 464-LNG-2018). The use of human tissues was approved by the intramural research programs of National Institutes of Health (protocol number: 2003-081).

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Biochemistry and Biomedical Sciences, Seoul National University, College of Medicine, 28 Yungun-dong, Jongro-gu, Seoul 110-799, South Korea. 2Transgenics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Building 35, Room 1A112, MSC 3707, 35 Convent Drive, Bethesda, MD 20892–3707, USA.

Received: 1 December 2017 Accepted: 15 January 2018

Published online: 23 January 2018

References

1. Lee AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet. 2009;373(9680):2055–66.
2. Burbulla LF, Krüger R. Converging environmental and genetic pathways in the pathogenesis of parkinson’s disease. J Neurol Sci. 2011;306(1-2):1–8.
3. Nalls MA, Parkrutz N, Lill CM. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for parkinson’s disease. Nat Genet. 2014;46(9):989–93.
4. Simón-Sánchez J, Schulte C, Bras JM, et al. Genome- wide association study reveals genetic risk underlying parkinson’s disease. Nat Genet. 2009;41(12):1308–12.
5. Healy DG, Falchi M, O’Sullivan SS, Bonifati V, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol. 2008;7(7):583–90.
6. Ahmed N. Advanced glycation endproducts–role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005;67(1):3–21.
7. Mallard LC. Action des acides amines sur les sucres: formation des melanoidines par voie methodique. C R Acad Sci (Paris). 1912;154:66–8.
8. Hodge JE. Dehydrated foods, chemistry of browning reactions in model systems. J Agric Food Chem. 1953;11(15):928–43.
9. Rahmadi A, Steiner N, Munch G. Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer’s disease. Clin Chem Lab Med. 2011;49(3):385–91.
10. Uribarri J, Cai W, Peppa M, et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci. 2007;62(4):427-33.
11. Van Puyvelde K, Mets T, Njemini R, et al. Effect of advanced glycation end product intake on inflammation and aging: a systematic review. Nutr Rev. 2014;72(10):638-50.
12. Munch G, Westcott B, Menini T, et al. Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids. 2012;42(4):1221-36.
13. Clynes R, Moser B, Yan S, et al. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med. 2007;7(8):743-51.
14. Herold K, Moser B, Chen Y, et al. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J Leukoc Biol. 2007;82(2):204-12.
15. Yan SS, Chen D, Yan S, et al. RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer’s disease. Front Biosci (Schol Ed). 2012;4:240-50.
16. Gomez A, Ferrer I. Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment. Acta Neuropathol. 2010;120(2):155-67.
17. Parisiadou L, Xie C, Cho HJ, et al. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci. 2009;29(44):13971-80.
18. Lin X, Parisiadou L, Gu XL, et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's disease-related mutant alpha-synuclein. Neuron. 2009;64(6):887-97.
19. Cho HJ, Liu G, Jin SM, et al. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein. Hum Mol Genet. 2013;22(3):608-20.
20. Ahmed N. Advanced glycation endproducts—role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005;67(1):3-21.
21. Hodge JE. Dehydrated food, chemistry of browning reactions in model system. J Agric Food Chem. 1963;1(15):928-43.
22. Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids. 2003;25(3-4):275-81.
23. Grillo MA, Colombatto S. Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases. Amino Acids. 2008;35(1):29-36.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit